CytomX Added to Russell 2000® Index
18 Diciembre 2015 - 3:57PM
CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical
company developing investigational Probody™ therapeutics for the
treatment of cancer, today announced that it has been added to the
Russell 2000®, Russell 3000® and Russell Global Indexes as part of
Russell Investments' annual reconstitution after market close on
December 18, 2015.
The Russell 2000® Index measures the performance of the
small-cap segment of the U.S. equity market and is a subset of the
Russell 3000®, representing approximately 10% of the total market
capitalization of that index. Membership in the Russell 2000® Index
includes automatic inclusion in the appropriate growth and style
indexes.
Russell indices are widely used by investment managers and
institutional investors for index funds and as benchmarks for both
passive and active investment strategies. Russell Investments
determines membership for each index based on objective market
capitalization rankings and style attributes. More than $5.7
trillion in assets are currently benchmarked to the Russell family
of indexes.
About CytomX Therapeutics
CytomX is an oncology-focused biopharmaceutical company
pioneering a novel class of investigational antibody therapeutics
based on its Probody technology platform. The company uses the
platform to create development-stage proprietary cancer
immunotherapies against clinically-validated targets, as well as to
develop first-in-class investigational cancer therapeutics against
novel targets. CytomX believes that its Probody platform has the
potential to improve the combined efficacy and safety profile of
monoclonal antibody modalities, including cancer immunotherapies,
antibody drug conjugates and T-cell-recruiting bispecific
antibodies. Probody therapeutics are designed to take advantage of
unique conditions in the tumor microenvironment to enhance the
tumor-targeting features of an antibody and reduce drug activity in
healthy tissues. Investigational Probody therapeutics are being
developed that address clinically-validated cancer targets in
immuno-oncology, such as PD-L1 against which the
company's clinical candidate CX-072 is directed.
Investigational Probody therapeutics are also being developed that
address novel, first in class targets, such as CD-166 against which
the company’s clinical candidate CX-2009 is directed. In addition
to its proprietary programs, CytomX is collaborating with strategic
partners including Bristol-Myers Squibb Company, Pfizer Inc., MD
Anderson Cancer Center, and ImmunoGen, Inc. For more information,
visit www.cytomx.com.
Forward-Looking Statements
This press release includes forward-looking statements. Such
forward-looking statements involve known and unknown risks,
uncertainties and other important factors that are difficult to
predict, may be beyond our control, and may cause the actual
results, performance or achievements to be materially different
from any future results, performance or achievements expressed or
implied in such statements. Accordingly, you should not rely on any
of these forward-looking statements. Our Probody platform is in
preclinical development, and the process by which a preclinical
technology could potentially lead to an approved product is long
and subject to significant risks and uncertainties. Applicable
risks and uncertainties include those relating to our preclinical
research and development and other risks identified under the
heading "Risk Factors" included in our filings with the SEC. The
forward-looking statements contained in this press release are
based on information currently available to CytomX and speak only
as of the date on which they are made. CytomX does not undertake
and specifically disclaims any obligation to update any
forward-looking statements, whether as a result of any new
information, future events, changed circumstances or otherwise.
Corporate Communications Contact:
Canale Communications
Ian Stone
ian@canalecomm.com
619-849-5388
Investor Contacts:
Trout Group
Pete Rahmer
prahmer@troutgroup.com
646-378-2973
CytomX Therapeutics (NASDAQ:CTMX)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
CytomX Therapeutics (NASDAQ:CTMX)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024